Healthcare and Life Science
Antibiotic use is not the only driver of superbugs
For the first time, researchers have analysed the impact of antibiotic use on the rise of treatment-resistant bacteria over the last 20 years in the UK and Norway. They show that while the increase in drug use has amplified the spread of superbugs, it is not the only driver. ...
A complimentary Cost-Savings Audit Breathe Technology
Breathe Technology is currently providing a free, cost-savings audit. A friendly, no-obligation and knowledgeable service. ...
Cancer drug discovery accelerated as hundreds of overlooked targets prioritised
A new, systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types, including breast, lung and ovarian cancers. By looking at multiple layers of functional and genomic information, researchers were able to create an unbiased, panoramic view...
How to start your health journey: key health skills for success
Creative Nutritionist writes...Happy New Year everyone! I hope you had a lovely Christmas break. If you are starting your health journey this January, and you are a bit confused as to what to do- don’t worry! I have you covered. I can help you move forward in your health journey so yo...
Evolving business models: Pharmaceutical incubators
As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts. A recent study found that 45% of drugs in the pipelines of 20 large biopharmaceutical companies were sourced externally in 2020. Sources of external ...
AI in drug discovery and development: Will it live up to the hype?
The recent explosion of generative artificial intelligence (AI) has fueled interest in and concern over the use of AI in drug discovery and research and development. ...
Where are we now? The promises and pitfalls of solid tumor CAR-T therapy
CAR T-cell therapy (CAR-T) has emerged as a therapeutic option with the ability to infiltrate and modulate the tumor microenvironment and control tumor growth. While normal T-cells with effector features have difficulty infiltrating the complex tumor microenvironment, ex vivo ...
The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe
The Patient Preference Survey aims to understand unmet needs related to riluzole management in people with Amyotrophic Lateral Sclerosis (ALS) and to identify which characteristics of a new formulation could better match their preferences. The survey involved 117 people with ALS (PALS) ...
Source of business for biosimilars in immunology
As of August 2023, there were 40 FDA-approved biosimilar products, including 25 commercially available products and four with interchangeable status.1 Adoption of biosimilars has continued to grow each year across therapeutic areas, and the increased competition they have generated...
Prism facilitate sale of Cambridge-based medtech design consultancy
Prism Corporate Broking are pleased to announce that we have facilitated the sale of medtech device design and development consultancy, Springboard Pro Ltd, to leading global healthcare packaging and medical device manufacturers, Sanner GmbH (Sanner Group), a company backed by Europe’s ...